Document Detail


90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma.
MedLine Citation:
PMID:  12777454     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Non-Hodgkin's lymphoma (NHL) is the most frequently diagnosed malignancy of the immune system, with more than 53,900 new cases diagnosed in 2002. Conventional cancer therapies cure many, but not the majority of, cases of the aggressive forms of NHL, and the more indolent and follicular forms of the disease that affect nearly half of all patients with NHL are considered incurable. In the absence of cure or survival benefits, treatments such as radioimmunotherapy that induce remission and prolong time off therapy are considered valuable. (90)Y-Ibritumomab tiuxetan recently became the first radioimmunotherapy agent to be approved for commercial use by the U.S. Food and Drug Administration. After reading this article, the nuclear medicine technologist should be able to understand the incidence and prevalence of NHL, describe the ibritumomab tiuxetan therapy protocol, explain specific infusion techniques for this protocol, list acquisition parameters after injection of (111)In-ibritumomab tiuxetan, and describe specific safety techniques to keep risk as low as reasonably achievable while performing the therapy protocol.
Authors:
Darlene M Fink-Bennett; Kathy Thomas
Related Documents :
17720334 - Cigarette smokers show steeper discounting of both food and cigarettes than money.
15448114 - Identification of the rabbit liver udp-glucuronosyltransferase catalyzing the glucuroni...
1779214 - Halothane and eucalyptol as alternatives to chloroform for softening gutta-percha.
7689454 - Fluoroquinolones: interaction profile during enteral absorption.
22044674 - Antibiosis of vineyard ecosystem fungi against food-borne microorganisms.
18818764 - Tracing the source of campylobacteriosis.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of nuclear medicine technology     Volume:  31     ISSN:  0091-4916     ISO Abbreviation:  J Nucl Med Technol     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-06-02     Completed Date:  2003-09-30     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  0430303     Medline TA:  J Nucl Med Technol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  61-8; quiz 69-70     Citation Subset:  IM    
Affiliation:
Department of Nuclear Medicine, William Beaumont Hospital, Royal Oak, Michigan 48072, USA. dfink@beaumont.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / diagnostic use,  therapeutic use*
Humans
Lymphoma, B-Cell / radionuclide imaging,  radiotherapy*
Neoplasm Recurrence, Local
Palliative Care / methods
Radiation Protection / methods
Radioimmunotherapy / methods*,  standards
Radiopharmaceuticals / diagnostic use,  therapeutic use
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted / methods*
Yttrium Radioisotopes / diagnostic use,  therapeutic use
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Radiopharmaceuticals; 0/Yttrium Radioisotopes; 0/ibritumomab tiuxetan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Presynaptic rat Kv1.2 channels suppress synaptic terminal hyperexcitability following action potenti...
Next Document:  Utility of posterior oblique views in (99m)Tc-DMSA renal scintigraphy in children.